Biofrontera Inc
BFRI0.900USD
+0.036+4.23%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
9.12MMarket Cap
LossP/E TTM
More Details of Biofrontera Inc Company
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
Company Info
Ticker SymbolBFRI
Company nameBiofrontera Inc
IPO dateOct 14, 2021
CEOProf. Dr. Hermann Luebbert, Ph.D.
Number of employees92
Security typeOrdinary Share
Fiscal year-endOct 14
Address120 Presidential Way,
CityWOBURN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01801
Phone17812451325
Websitehttps://www.biofrontera-us.com/
Ticker SymbolBFRI
IPO dateOct 14, 2021
CEOProf. Dr. Hermann Luebbert, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
152.71K
+903.95%
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
87.50K
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Mr. George Jones
Mr. George Jones
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
152.71K
+903.95%
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
87.50K
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
No Data
By RegionUSD
Name
Revenue
Proportion
United States
37.32M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Sep 18
Updated: Thu, Sep 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AIGH Capital Management, LLC.
8.57%
Rosalind Advisors, Inc.
6.04%
Hewlett Fund, L.P.
5.16%
Biofrontera AG
3.75%
Lytton (Laurence W)
2.87%
Other
73.61%
Shareholders
Shareholders
Proportion
AIGH Capital Management, LLC.
8.57%
Rosalind Advisors, Inc.
6.04%
Hewlett Fund, L.P.
5.16%
Biofrontera AG
3.75%
Lytton (Laurence W)
2.87%
Other
73.61%
Shareholder Types
Shareholders
Proportion
Private Equity
9.12%
Corporation
8.91%
Hedge Fund
8.86%
Individual Investor
5.13%
Investment Advisor/Hedge Fund
2.72%
Investment Advisor
0.90%
Research Firm
0.21%
Venture Capital
0.11%
Other
64.05%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
43
3.55M
36.44%
-1.43M
2025Q1
47
3.28M
35.88%
-1.71M
2024Q4
48
3.72M
54.29%
+158.24K
2024Q3
43
3.76M
68.24%
+377.12K
2024Q2
45
3.39M
76.90%
-69.63K
2024Q1
45
3.44M
88.71%
+1.56M
2023Q4
40
853.94K
58.17%
+32.52K
2023Q3
43
649.68K
47.81%
-61.68K
2023Q2
41
673.17K
109.72%
-35.12K
2023Q1
40
667.34K
54.59%
-30.23K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AIGH Capital Management, LLC.
914.21K
9.68%
+556.50K
+155.57%
Apr 22, 2025
Rosalind Advisors, Inc.
644.39K
6.82%
--
--
Apr 22, 2025
Hewlett Fund, L.P.
550.22K
5.82%
-97.23K
-15.02%
Apr 22, 2025
Biofrontera AG
400.00K
4.23%
--
--
Dec 20, 2024
Lytton (Laurence W)
306.70K
3.25%
-228.98K
-42.75%
Mar 31, 2025
Armistice Capital LLC
291.15K
3.08%
+141.15K
+94.10%
Sep 30, 2024
Worth Venture Partners, LLC
374.44K
3.96%
-70.34K
-15.82%
Mar 31, 2025
Luebbert (Hermann)
15.21K
0.16%
--
--
Apr 22, 2025
Matejka & Partner Asset Management GmbH
63.80K
0.68%
--
--
Nov 30, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Date
Type
Ratio
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
